Etodolac

Uses your system voice; voice and rate in settings.

Snapshot

≈ 2 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Etodolac is a nonsteroidal anti-inflammatory drug (NSAID). It was patented in 1971 and approved for medical use in 1985. It was approved in the U.S. in 1991. In 2023, it was the 296th most commonly prescribed medication in the United States, with more than 400,000 prescriptions.

Etodolac is a nonsteroidal anti-inflammatory drug (NSAID). It was patented in 1971 and approved for medical use in 1985. It was approved in the U.S. in 1991. In 2023, it was the 296th most commonly prescribed medication in the United States, with more than 400,000 prescriptions.

Medical uses

NSAIDs are used for the management of mild to moderate pain, fever, and inflammation. They work by reducing the levels of prostaglandins, which are chemicals that are responsible for pain and the fever and tenderness that occur with inflammation. Etodolac blocks the cyclooxygenase (abbrev. COX) enzymes which form prostanoids, resulting in lower concentrations of prostaglandins. As a consequence, inflammation, pain and fever are reduced. Etodolac is 179 times more selective at blocking COX-2 than COX-1. Unlike rofecoxib, both etodolac and celecoxib can fully inhibit COX-1 and are designated as having "preferential selectivity" toward COX-2. The R-enantiomer of etodolac is inactive against COX enzymes, but inhibits beta-catenin levels in hepatoma cells. In the UK, Etodolac is licensed for the treatment of inflammation and pain caused by osteoarthritis and rheumatoid arthritis.

Pregnancy and nursing

Etodolac is generally avoided during pregnancy and nursing. NSAIDs may cause adverse cardiovascular effects in the fetus during pregnancy. In October 2020, the U.S. Food and Drug Administration (FDA) required the prescribing information to be updated for all nonsteroidal anti-inflammatory medications to describe the risk of kidney problems in unborn babies that result in low amniotic fluid. They recommend avoiding NSAIDs in pregnant women at 20 weeks or later in pregnancy.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1316039301 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

13 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.